Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) both emerged in the second half of the 20th century, and chronic infection with these agents is among the greatest challenges facing health care in the United States and worldwide. Despite tremendous advances in treatment and management of HIV and HCV, individuals with HIV/HCV coinfection experience a more complicated disease course and treatment. Recognition of the important role that host factors, such as IL28B genotype, have in response to HCV therapy and the emergence of new effective therapies for HCV are actively reshaping the standard of care. These advances may translate into more effective treatment and management of patients with chronic HCV and HIV coinfection in the years ahead.
A, From a biopsy in 2008, hematoxylin-eosin stain demonstrates moderate portal inflammation, moderate interface hepatitis, and mild steatosis, and Masson stain shows bridging fibrosis (blue). B, Repeat biopsy in 2010 shows hematoxylin-eosin stain demonstrating decreased inflammation and decreased steatosis, and Masson stain showing fibrosis (blue), which is unchanged. Original magnification ×200.
Nonstructural 3/4A (NS3/4A) serine protease inhibitors are directly acting antiviral agents that interfere with viral NS3 serine protease and its cofactor, NS4A. In the hepatitis C virus (HCV) life cycle, viral NS3/4A serine protease cleaves the HCV polyprotein into small nonstructural proteins that are necessary for viral replication within the hepatocyte. Two drugs in this class, telaprevir and boceprevir, were recently approved by the US Food and Drug administration. ssRNA indicates single-stranded RNA.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 23
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.